Nob Hill Therapeutics is a pioneering biotechnology company based in Albuquerque, New Mexico, focused on developing advanced drug delivery systems. Established in 2016, the company was built on technology licensed from the University of New Mexico's tech transfer arm. Nob Hill has notably raised a total of approximately $3.67 million in funding over several rounds, with key investments from entities such as Tramway Venture Partners and VIC Technology Venture Development. The company is best known for its flagship product, the "DryNeb," a dry powder nebulizer designed to offer efficient pharmacological delivery to the lungs.
Attribute | Information |
---|---|
Founding Date | 2016 |
Headquarters | Albuquerque, New Mexico |
Founders | VIC Technology Venture Development |
Revenue | Not publicly disclosed |
Profits | Not publicly disclosed |
Key Investors | Tramway Venture Partners, VIC Technology Venture Development, TCA Venture Group |
Industry | Biotechnology, Drug Delivery |
Number of Employees | 4 |
Nob Hill Therapeutics was founded to leverage advanced pulmonary drug delivery systems emerging from innovative research at the University of New Mexico. Initially founded by VIC Technology Venture Development in 2016, the company sought to address significant gaps in the effective delivery of respiratory medications. Early funding rounds focused on validating their DryNeb technology, capable of more efficient delivery of drugs to the lungs than existing inhalers. These efforts culminated in gathering substantial interest from venture capitalists, leading to minor pivots in the company's operational focus as it moved towards clinical trials.
Nob Hill Therapeutics focuses its efforts on their DryNeb technology, a notable advancement in the realm of drug delivery devices. DryNeb stands out due to its capability to deliver a wide array of medications directly to a patient's lower respiratory tract, which has applications in treating illnesses such as cystic fibrosis and pulmonary fibrosis.
The company's strategic path forward involves partnerships with leading pharmaceutical companies, with a goal to incorporate their technology into broader therapeutic regimens. Their technology platform looks to transform how large dosages of medication can be delivered effectively to the lungs, opening new possibilities in treating pulmonary diseases.
Nob Hill Therapeutics operates primarily within the biotechnology sector, focusing on novel drug delivery mechanisms that aim to revolutionize treatments for respiratory diseases. Its DryNeb platform provides a critical competitive advantage in the market, offering a scalable solution to deliver medications directly to the lung tissues, surpassing traditional inhalers. This has positioned Nob Hill favorably among its competitors.
The company is actively engaged in negotiations with pharmaceutical firms to form partnerships that will bolster the clinical testing of its devices. The anticipation of entering clinical trials by the end of 2025 marks a pivotal point in its operational timeline.
Nob Hill Therapeutics exemplifies a focused and innovative approach within the biotechnology landscape, particularly in advancing respiratory healthcare through its patented drug delivery systems. As the company edges closer to clinical trials, its DryNeb technology has the potential to redefine treatment protocols for various lung-related diseases. Looking forward, with strategic partnerships and continued technological evolution, Nob Hill is poised to significantly impact both the drug delivery market and patient care within respiratory medicine.